Reta-Peptide Multi-Target Agonists Drive 2026 Obesity Market: 78% Efficacy vs. Semaglutide, $45B Projected by 2030
Abstract: Reta-peptide (retatrutide), a triple GIP/GLP-1/glucagon receptor agonist, demonstrates 78% superior efficacy over semaglutide in Phase 2 trials, driving a projected $45B obesity market by 2030. Unlike single-target semaglutide, reta-peptide achieves enhanced weight loss (24.2% vs. 15-18%) via multi-target synergy, though with higher gastrointestinal side effects. Key market trends favor multi-agonists over mono-agonists, with Novo Nordisk (semaglutide) and Eli Lilly (retatrutide) leading. Product selection criteria prioritize purity (>98%), cold-chain logistics (2-8°C), and GMP-certified facilities. The shift from injectable to oral formulations and expanding indications (NASH, CVD) underscore industry growth, while regulatory approvals (FDA/EMA) remain critical for market entry.